Applications in Lung Cancer

M. Stuschke, H.-P. Heilmann, Lunge und Mediastinum Strahlentherapie. pp. 683- 718 ,(1996) , 10.1007/978-3-642-79432-2_35

J-L Pujol, Carestia, J-P Daurès, Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent British Journal of Cancer. ,vol. 83, pp. 8- 15 ,(2000) , 10.1054/BJOC.2000.1164

Luka Milas, Frederick F. Lang, Cordula Petersen, Sven Petersen, Philip J. Tofilon, Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clinical Cancer Research. ,vol. 6, pp. 2513- 2520 ,(2000)

M. H. Cullen, L. J. Billingham, C. M. Woodroffe, A. D. Chetiyawardana, N. H. Gower, R. Joshi, D. R. Ferry, R. M. Rudd, S. G. Spiro, J. E. Cook, C. Trask, E. Bessell, C. K. Connolly, J. Tobias, R. L. Souhami, Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non–Small-Cell Lung Cancer: Effects on Survival and Quality of Life Journal of Clinical Oncology. ,vol. 17, pp. 3188- 3194 ,(1999) , 10.1200/JCO.1999.17.10.3188

K. S. Albain, R. S. Swann, V. R. Rusch, A. T. Turrisi, F. A. Shepherd, C. J. Smith, D. R. Gandara, D. H. Johnson, M. R. Green, R. C. Miller, Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309) Journal of Clinical Oncology. ,vol. 23, pp. 7014- 7014 ,(2005) , 10.1200/JCO.2005.23.16_SUPPL.7014

W.K. (Bill) Evans, Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer Cancer Treatment Reviews. ,vol. 30, pp. 655- 659 ,(2004) , 10.1016/J.CTRV.2004.08.002

K S Albain, V W Rusch, J J Crowley, T W Rice, A T Turrisi, J K Weick, V A Lonchyna, C A Presant, R J McKenna, D R Gandara, Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. Journal of Clinical Oncology. ,vol. 13, pp. 1880- 1892 ,(1995) , 10.1200/JCO.1995.13.8.1880

N C Choi, R W Carey, W Daly, D Mathisen, J Wain, C Wright, T Lynch, M Grossbard, H Grillo, Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer Journal of Clinical Oncology. ,vol. 15, pp. 712- 722 ,(1997) , 10.1200/JCO.1997.15.2.712

W Eberhardt, H Wilke, G Stamatis, M Stuschke, A Harstrick, H Menker, B Krause, M R Müeller, M Stahl, M Flasshove, V Budach, D Greschuchna, N Konietzko, H Sack, S Seeber, Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. Journal of Clinical Oncology. ,vol. 16, pp. 622- 634 ,(1998) , 10.1200/JCO.1998.16.2.622

N Murray, P Coy, J L Pater, I Hodson, A Arnold, B C Zee, D Payne, E C Kostashuk, W K Evans, P Dixon, Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology. ,vol. 11, pp. 336- 344 ,(1993) , 10.1200/JCO.1993.11.2.336